Their statement, to be published in the Journal of Clinical Oncology and getting early online launch, describes how treatment with the experimental drug cediranib decreased edema and improved survival in three mouse models of glioblastoma. ‘Our findings suggest that antiangiogenesis therapy can increase patient survival even in the face of persistent tumor development,’ says Rakesh K. Jain, PhD, director of the Steele Laboratory in the MGH Department of Radiation Oncology, the study’s co-senior writer. ‘In glioblastoma scientific trials, it is necessary to separate survival analysis from that of tumor response to therapy, because so many factors combine to cause patient deaths.’ Cediranib inhibits the potent angiogenesis factor VEGF, which may be abundantly within glioblastomas and play a critical role in tumor blood vessel formation.Cerebral Palsy Family Network and Get rid of CP possess kicked off Are a symbol of CP, to raise money to greatly help extend research presently underway at Duke University by stem cell pioneer Dr. Joanne Kurtzberg. Dr. Kurtzberg's work holds tremendous prospect of helping kids with cerebral palsy lead normal or even more functional lives, but like most research coping with cerebral palsy, it needs financial support to survive, said Lisa Viele, mother or father with CPFN. Donations are being approved through the CPFN Facebook web page. Related StoriesResearchers discover that stem cell treatment may reduce cognitive impairment related to dementia with Lewy bodiesSCT, Thermo Fisher Scientific collaborate to advance advancement of cardiac disease modelsNYSCF, CBR collaborate to customize creation of high-quality stem cell linesDr.